A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

NCT06500676 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D Mutations
Advanced Solid Tumors

Interventions

DRUG: GFH375

Sponsor

Genfleet Therapeutics (Shanghai) Inc.